The art of managing human immunodeficiency virus infection: A balancing act

Clinical Infectious Diseases

Volumn 49, Issue 10, 2009, Pages 1602-1604

  Reiss, Peter ^a  

^a Ctr Poverty Related Communic Dis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR; LAMIVUDINE; PROTEINASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALKALINE PHOSPHATASE BLOOD LEVEL; BONE MINERALIZATION; CARDIOVASCULAR RISK; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; LIPOATROPHY; NONHUMAN; NOTE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG TOXICITY; HIV INFECTIONS; HUMANS; LAMIVUDINE; PHOSPHONIC ACIDS; TREATMENT OUTCOME;

EID: 72849123079     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/644770     Document Type: Note

References (13)

1. Calmy A, Hirschel B, Cooper DA, Carr A. A new era of antiretroviral drug toxicity. Antivir Ther 2009; 14:165-179
2. Mallal S, Phillips E, Carosi G, et al; for the PREDICT-1 Study Team. HLA-B.*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579
3. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofoviremtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-1601 (in this issue).
4. Sabin CA, Worm SW, Weber R, et al; for the D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-26 (erratum: Lancet 2008; 372:292).
5. Lang S, Mary-Krause M, Cotte L, et al. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4 [abstract 43LB]. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montreal, Canada). 2009.
6. The SMART/INSIGHT and the D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17-24.
7. Cutrell AG, Brothers CH, Hernandez JE, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 Glaxo- SmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20-28
8. Benson C, Ribaudo H, Zheng E, et al; for the ACTG A5001/ALLRT Protocol Team. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001 [abstract 721]. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montreal, Canada). 2009.
9. Desquilbet L, Jacobson LP, Fried LP, et al. HIV- 1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci 2007; 62:1279-1286 (Pubitemid 350287617)
10. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
11. Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47: 542-553
12. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-241 (Pubitemid 351160160) (Pubitemid 351160160)
13. World Health Organization 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases. Available at: http://www.who.int/nmh/ Actionplan-PC-NCD-2008.pdf. Accessed 13 July 2009.